Exploring the Evolution of Quality of Life and Emotional Distress Among Cancer Patients Participating in Mind-body Therapies

NCT07283627 | Enrolling By Invitation

• 1 other identifier: 2025-00543
• Study Type: observational
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

Cancer incidence is increasing worldwide, and although survival rates have improved thanks to advances in treatment and early detection, many patients continue to experience reduced quality of life (QoL), anxiety, depression, and distress. Mind-body therapies (MBTs)-including mindfulness, laughter yoga, and art therapy-are increasingly integrated into supportive oncology care. Evidence suggests these therapies may improve psychosocial well-being; however, existing research often suffers from methodological limitations, small samples, and limited generalizability. The OTIUM centers in Geneva and Meyrin offer structured MBT programs to cancer patients. This project aims to evaluate the evolution of QoL and emotional distress in patients participating in one of these therapies, using validated patient-reported outcome measures (PROMs).

Conditions

Cancer; Mind-Body Therapies

Keywords

Cancer; Supportive care; Patient-reported outcomes; Emotional distress; Mind-body therapies; Quality of life; Mindfulness; Laughter yoga; Art therapy; Integrative oncology

Outcome Measures

Primary Outcomes (1)

• Quality of life

  The primary variable of interest is the total score on the EORTC QLQ-C30, measured at baseline and at the end of treatment, on average 8 weeks after start of treatment. The EORTC QLQ-C30 is scored on a 0 to 100 scale, with higher scores indicating better quality of life for the global health status/quality of life scale. This outcome was selected because it is the most widely used PROM, which facilitates interpretation and comparison with existing literature, and enables us to better assess the quality of care we provide.

  From enrollment to the end of treatment at (approximately) 8 weeks

Secondary Outcomes (1)

• Emotional distress

  From enrollment to the end of treatment at (approximately) 8 weeks

Study Arms (1)

OTIUM Minb-body therapy cohort

This cohort includes adult cancer patients participating in one specific mind-body therapy (MBT) offered at the OTIUM Centers in Geneva and Meyrin. Eligible participants take part in a structured program-mindfulness, laughter yoga, or art therapy-delivered in a group format over approximately 8 to 10 weeks. The cohort is designed to evaluate changes in quality of life and emotional distress associated with participation in the selected MBT. All participants complete standardized patient-reported outcome measures (EORTC QLQ-C30 and HADS) before and after the therapy.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Study participants will be selected from individuals receiving supportive oncology services at the OTIUM Centers located in Geneva and Meyrin, Switzerland. These centers provide mind-body therapies as part of routine integrative care for adults living with or recovering from cancer. Patients typically come from the greater Geneva region and may be referred by oncologists at Hôpital de La Tour or may self-present to the centers to participate in non-pharmacological supportive programs. The study population therefore reflects a real-world clinical population engaged in mind-body therapies within an outpatient supportive care setting.

You may qualify if:

• Patient diagnosed with cancer
• Acceptance and signature of an informed consent form
• Age of majority
• Completion of one of the therapies concerned.

You may not qualify if:

• Withdrawal of the signed informed consent form
• Metastatic cancer
• Cancer recurrence
• Drugs use against stress
• Memory disorders
• History or current use of a MBT

Sponsors & Collaborators

• La Tour Hospital: lead
• OTIUM foundation: collaborator

Study Sites (1)

La Tour Hospital

Meyrin, Canton of Geneva, 1217, Switzerland

Location

MeSH Terms

Conditions

Neoplasms

Study Officials

• Anthony Pernoud, MSc

  La Tour Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Clinical Project Manager

Study Record Dates

• First Submitted: December 4, 2025
• First Posted: December 16, 2025
• Study Start: December 1, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): January 1, 2027
• Last Updated: December 24, 2025

Record last verified: 2025-12

Locations

CH (1)